{"analyses":[{"groupDescription":"Paired t-tests were used to compare differences of NTX cytokine levels at study entry versus end-of-study.","groupIds":["OG000"],"nonInferiorityComment":"single group","nonInferiorityType":"OTHER","pValue":"<0.05","statisticalMethod":"t-test, 1 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}],"title":"NTX level ≤ 50 nmol/mmol Cr"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"NTX level > 50 nmol/mmol Cr"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Number of participants with urinary NTX levels less than or equal to 50 nmol/mmol creatinine (Cr) for the duration of study followup, following a single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1). Dose administration was followed by Aminobisphosphonates (aBP) treatment cessation during study period.","groups":[{"description":"Single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1) followed by Aminobisphosphonates (aBP) treatment cessation during study period.","id":"OG000","title":"Zoledronic Acid"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr","type":"PRIMARY","unitOfMeasure":"Participants"}